Inherent damage in vagus nerve that controls the movement of food through the digestive tract is a major cause of diabetic gastroparesis. Damage in the vagus nerve leads to malfunctioning of muscles of the stomach and intestines and the movement of food is slowed or stopped.

The global Diabetic Gastroparesis Treatment Market is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027.

Global Diabetic Gastroparesis Treatment Market: Drivers

Development of effective therapeutics for the treatment of diabetic gastroparesis is expected to propel growth of the global diabetic gastroparesis treatment market over the forecast period. For instance, according to research presented at Digestive Disease Week, a medical meetings by Healthcare Convention & Exhibitors Association (HCEA), in June 2019, Velusetrag, an oral, highly selective 5-hydroxytryptamine receptor 4 agonist, effectively reduced symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis.

Global Diabetic Gastroparesis Treatment Market: Opportunities

Developments in endoscopic ultrasonography are expected to offer lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. Injection of botulinum toxin with direct ultrasonographic visualization to the muscularis propria of the pyloric sphincter can be effective in the treatment of diabetic gastroparesis. Moreover, endoscopic transpyloric stent placement is also expected to aid in treatment of the disease.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/diabetic-gastroparesis-treatment-market-3603

Global Diabetic Gastroparesis Treatment Market: Restraints

The reported incidence of diabetic gastroparesis is very low worldwide as the symptoms are common with general nausea, vomiting, and gastroesophageal reflux disease. Furthermore, the use of non-prescription drugs for the treatment of the symptoms of the disease restricts diagnosis of stage 1 and stage 2 gastroparesis. Such factors are also expected to propel growth of the global diabetic gastroparesis market.

Key Takeaways:

Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period. Drugs are the first choice of treatment for any kind of ailment, and surgical options are often used when pharmacological treatment is not producing any results or the disease has become life threatening. Patients as well as physicians are expected to prefer treatments with drugs as first line therapy which is expected to support growth of the market.

The hospital pharmacies segment held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 48.4% share in terms of value, followed by retail pharmacies and online pharmacies, respectively. Patients are expected to visit hospitals frequently for routine check-ups as well as to renew their prescriptions and later buy the medicines from hospital pharmacies.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3603

Moreover, in countries in Asia Pacific regions patients often buy medicines from hospital pharmacies itself. These factors are expected to support growth of the segment over the forecast period.

The Antiemetic Agents segment held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 53.8% share in terms of value, followed by gastroprokinetic agents, and botulinum toxin, respectively. Factors such as widespread presence of cheaper generic antiemetic agents, easy availability of drugs in pharmacies, and large number of manufacturers is expected to support growth of the segment.

Market Trends

Gastric electrical stimulation can be used for the treatment of diabetic gastroparesis. For instance, in November 2019, researchers from University of Louisville reported that gastric electrical stimulation is beneficial for improving the treatment of diabetic gastroparesis.

Players in the market are focused on raising funds. For instance, in January 2018, Neurogastrx raised US$ 45 million for building its management team. The company’s drug candidate, NG-101, is designed for the treatment of gastroparesis.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3603

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737